Veterinary vaccines

Details Veterinary vaccines Veterinary vaccines

2000-05-23

2003-02-25

Smith, Lynette R. F. (Department: 1645)

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

C424S234100, C424S184100

Reexamination Certificate

active

06524592

ABSTRACT:

The present invention relates to novel vaccine compositions for parenteral administration, methods for their use and to processes for their preparation. Bacterial and viral diseases of sheep, such as Clostridial diseases, cause considerable economic damage in the agriculture industry. Vaccination is therefore a very important means of controlling these diseases.
Many currently available vaccines are comprised of killed antigens, whether inactivated bacterial cells, viral particles or cellular components, absorbed onto alkali earth metal salts (i.e. aluminium phosphate or aluminium hydroxide) or as water in oil emulsions. For these vaccines it is recommended that naive animals (i.e. animals which have not been previously vaccinated) are treated in a two stage dose regime consisting of an initial dose and a second booster dose several weeks later. The action of the booster dose raises the antibody titre to a level that may sustain protection from a disease causing challenge organism for an extended period. Animals undergoing this vaccination program are usually mustered each year for revaccination. Clearly such initial two-dose administration is time consuming and expensive and is therefore undesirable.
The aluminium based vaccines have been found to have relatively short duration of protection while water-in-oil emulsion vaccines have a longer duration of protection but have been found to be unsuitable for use because they cause unacceptable lesions at the injection sites of the animals (‘Experimental Clostridial Oil Emulsion Vaccines’ Thomson R O. and Batty I., Bull. Off. int Epiz. 1967 67 (11-12)1569-1581; ‘The Immunogenicity of a multicomponent Clostridial Oil Emulsion Vaccine in sheep’ Thomson et al The Veterinary Record, Jul. 26, 1969). In 1976 Jansen et al. reported the immune response of
Cl. botulinum
C and D toxoids in a water-in-oil emulsion vaccine and noted that the two-stage aluminium based vaccine was not boosted by the second dose to the same extent as the water in oil compositions (Jansen, B C, Knoetze, P C & Visser, F; Onderstepoort J Vet Res, 43(4) 165-174 (1976)). However, the water in oil compositions gave an undesirable granulomatous swelling resulting from subcutaneous injection of the vaccine in a large percentage of animals which is a severe disadvantage for the vaccine's commercial use.
WO91/00106 discloses multi-phase emulsions suitable for administering active substances or antigens by injection of the water in oil in water type. These emulsions are produced from pharmaceutically acceptable emulsifiers which when dissolved in an injectable oil, form a homogeneous clear phase and have inversion points approaching the temperature of human or animal bodies. The oils contained in the emulsions include mineral, vegetable or animal oils, and synthetic hydrocarbons. It was observed that these vaccines were well tolerated in pigs and did not cause any local reactions, abscesses or necroses. However, no data were provided regarding the level and duration of the immune responses.
The applicants provide vaccines which are suitable for the prevention of clostridial diseases of sheep and in particular lambs, providing an effective immunity for up to a year or more following a single injection or dose. Therefore, the present invention addresses the problems associated with known vaccines, providing a level of effective immune response in sheep for the period of approximately one year or more following a single injection or dose of vaccine. The present invention also provides vaccines which provide an effective immunity against each of a number of diseases for up to a year or more following a single injection or dose of a multivalent vaccine. The selection of an adjuvant which enhances the antigenic response to clostridial antigens in sheep is thus a problem addressed by the invention. The selection of an adjuvant which enhances the antigenic response to each of a number of micro-organisms in sheep is a particular problem addressed by the invention.
Thus according to the present invention there is provided a sheep vaccine composition comprising:
a) an oily adjuvant acceptable for veterinary purposes comprising:
i) a white mineral oil having a molecular weight of about 250 to 300 and
ii) a mannitol oleate emulsifier and
b) an aqueous phase comprising one or more clostridial antigens.
When used herein the term “sheep” refers to lambs as well as developing and mature sheep. The vaccines of the invention are particularly useful in the vaccination of lambs.
The vaccine composition is an injectable emulsion of the water in oil type and preferably has a viscosity of about 200 mPas or less, more preferably about 100 mPas to about 150 mPas. The white mineral oil is preferably between about 50% and about 70% by weight of the emulsion more preferably between about 53% and about 63% by weight of the emulsion. The mannitol oleate emulsifier is preferably between about 2% and about 10% by volume of the emulsion more preferably between about 3% and about 7%.
The white mineral oil has a molecular weight of about 250 to 300, preferably about 270 to 290, more preferably about 280. The oil is preferably one which is liquid at 4° C. and has a viscosity lower than 100 mPas at 25° C. It preferably has a density at 20° C. of about 815 to 840 kg/m
3
, more preferably about 817 to 837 kg/m
3
. The dynamic viscosity of the oil at 25° C. is preferably about 5 to 15 mPas, more preferably about 6 to 13 mPas. The oil preferably has a kinematic viscosity at 40° C. of about 5 to 10 mm
2
/s, more preferably about 7.5 mm
2
/s. Preferred embodiments of the invention include the commercially available oil Marcol 52 which is supplied by ESSO.
The mannitol oleate emulsifier is preferably an anhydromannitol ether octadecanoate. Preferred emulsifiers have a viscosity at 25° C. of about 300 to 400cP, more preferably about 340 to about 360 cP, particularly preferred embodiments are those in which the emulsifier has a viscosity of about 350 cP. The emulsifier preferably has a specific gravity at 20° C. of about 0.8 to 1.0, more preferably of about 0.95 to about 0.99, particularly suitable are those with a specific gravity at 20° C. of about 0.97. Particularly preferred emulsifiers are those with a refractive index at 25° C. of about 1.4 to 1.5, more preferably of about 1.47 to 1.48, particularly those with a refractive index at 25° C. of about 1.4748 to 1.4758. Particularly preferred oils are the commercially availably ones Montanide 80, Montanide 103 and Montanide 888 supplied by SEPPIC SA, 75 Quai D-Orsay, 75007 Paris. Montanide 103 and Montanide 888 being more preferred and Montanide 888 being most preferred.
It will be apparent to a person of skill in the art that the proportion of oily adjuvant to aqueous phase included in the emulsion can be adjusted to optimise vaccines including particular antigens and for use in particular animals. It can also be modified to optimise vaccines for administration at a particular site.
The site of administration may also affect the efficacy and/or the site reactions caused by the vaccines. It will be apparent to a person of skill in the art that the site of administration can be selected so as to optimise the effects of vaccines including particular antigens and for use in particular animals. The vaccines exemplified herein were found to be efficacious regardless of site of administration, however site reactions from the exemplified vaccines were more numerous when they were administered at the brisket.
Clostridial antigens suitable for use in the compositions of the present invention include
Clostridium perfringens
type A, B, C and D,
Clostridium septicum, Clostridium tetani, Clostridium chauvoei, Clostridium novyi
type B,
Clostridium sordelli, Clostridium haemolyticum, Clostridium chauvoei
and
Clostridium botulinum
C and D. Suitable antigens include those which are useful in the treatment of diseases such as Lamb dysentery, Pulpy Kidney disease (enterotosemia), Malignant Oedema (blood poisoning), Tetanus, Blackleg disease and Black disease.
Antigens su

Affiliated with

Also associated with

Rating

Veterinary vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Veterinary vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Veterinary vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3180434